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doi:10.1016/j.jtcvs.2003.12.015The use of adjunctive staging techniques in patients with potentiallyresectable non–small cell lung cancer (NSCLC) will improve sur-vival in two ways, by selecting patients for whom surgery would befutile and by selecting patients for whom induction or adjuvanttherapy could improve survival. Various biologic staging parametershave been applied to the primary tumor,1 lymph nodes,2 bone mar-
row,3 and serum (Brooks and colleagues, unpublished data) with demonstrated
effective stratification in terms of survival and risk of recurrence. Furthermore,
analysis of molecular characteristics of the tumor may stratify patients according to
response to chemotherapy.4 The strategy of pleural lavage cytologic study may
accomplish one, both, or neither of these objectives, depending on how it is applied.
The efficacy of pleural lavage cytologic examination was investigated by Lim
and colleagues5 in a series of 292 patients who underwent thoracotomy for lung
cancer. In this series, 13 (4.5%) of 292 of patients were found to have positive
cytologic results; however, only 5 of the 292 patients had pathologic stage I or II
disease (irrespective of the pleural cytologic result), and the remaining patients had
disease already classified as stage IIIA (5 patients), stage IIIB (2 patients), or stage
IV (1 patient). Thus few patients had disease upstaging as a result of this technique.
For a staging technique (conventional or biologic) to be considered effective, a
significant portion of patients should be affected; it appears that only 1% to 2% of
patients would have upstaging as a result of pleural cytologic examination.
Positive cytologic results, in addition to pathologic stage, had a negative impact
on survival in this series. Unfortunately, the follow-up is incomplete; median
follow-up is only 15 months (range 1-40 months). As more patients with early stage
disease and negative pleural cytologic results have relapses in time, the stratification
effect of positive pleural cytologic results may be diminished. Lim and colleagues5
compared the survival of a group of 17 patients with stage IIIB (T4) disease with the
patients in the study with positive pleural cytologic results, a comparison that is not
germane to their study. Of the 17 patients with stage IIIB disease, 15 of 17 had T4
status defined by the presence of a satellite nodule only. It is well known that the
survival in this subgroup is much better than those of the malignant pleural effusion
or N3 subgroups.
The goals of preoperative staging are to select patients who would benefit from
induction therapy and to select patients for immediate resection. As currently
described, pleural lavage performed at the time of thoracotomy will not effectively
select patients for induction therapy. Furthermore, this technique will not effectively
exclude patients from futile surgery, because a significant component of the risk of
surgery is the thoracotomy itself. Patients who undergo futile thoracotomy may
suffer in one of the following ways: the inherent risk of the procedure (complica-
tions, including death), postoperative pain, delay in receiving chemotherapy, a
higher risk of incomplete chemotherapy dosing, and delay or interruption of radi-
ation therapy. However, performance of the procedure preoperatively, either per-
cutaneously or with minimally invasive techniques, combined with real-time cyto-
logic analysis, may make this strategy successful.
Regarding assignment of treatment, there is no evidence that induction or
adjuvant therapy would be useful in this population of patients (those with positive
pleural cytologic results), but this may be a question for future studies. Currently,
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pleted multi-institutional trials: Cancer and Leukemia
Group B (CALGB) 159902: Markers of Pleural Involve-
ment in NSCLC; and American College of Surgeons On-
cology Group (ACOSOG) Z0040: Prognostic Significance
of Occult Metastases in NSCLC. In addition, other emerg-
ing technologies may improve risk stratification and selec-
tion of therapy for patients with potentially resectable
NSCLC. Intraoperative assessment of lymph nodes with
real-time polymerase chain reaction may improve the ability
to detect occult mediastinal lymph node involvement at
mediastinoscopy. The development of the sentinel node
technique for lung cancer (CALGB 140203) may allow
complete molecular analysis of a single lymph node station
to determine the degree of nodal involvement.
Stage-specific therapy of NSCLC depends on thorough
preoperative and intraoperative staging. Techniques that
improve risk stratification may identify subgroups of pa-
tients in whom induction or adjuvant therapy is beneficial.
Currently, induction therapy is reserved for patients with
advanced disease, although ongoing protocols offering in-
duction therapy to a wider range of patients may demon-
strate an advantage to that strategy. Recent studies have
demonstrated that adjuvant chemotherapy is associated with
a marginal (4%-5%) increase in survival among patients
with completely resected lung cancer (stage I-III).6,7 To
improve overall survival of patients with NSCLC, we must
continue to investigate novel staging and treatment strate-
gies. Surgeons should be intimately involved with the de-
948 The Journal of Thoracic and Cardiovascular Surgery ● Aprisign, execution, and review of these studies to ensure clin-
ical and scientific relevance, clinical quality, and
appropriate tissue acquisition.
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